FDA Estimates GSK Seizure Involves $4 Bil. Worth Of Product
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's seizure of GlaxoSmithKline's Paxil CR and Avandamet is the agency's largest in terms of monetary value, involving $4 bil. worth of product, the agency said
You may also be interested in...
GSK Paxil, Avandamet Seizure Will Have “Ripple Effect” On GMPs, FDAer Says
FDA hopes the seizure will serve as a warning to other manufacturers that do not heed guidelines for good manufacturing practices. The decision to bypass other regulatory options was made in consultation with Acting Commissioner Crawford. FDA is currently negotiating a consent decree with GSK.
Another Chance For VALID? Negative Reaction To FDA’s LDT Proposal May Reopen Legislative Talks
All of the witnesses testifying to a House E&C Committee hearing said they preferred the flexibility and targeted enforcement of the VALID Act to FDA’s proposed rule. Will Congress finally be spurred to act?
US FDA Advisory Panels May Look Different Across Centers, Despite Efforts To Standardize Process
As FDA is readying to go back to in-person advisory committee meetings this fall, the centers have different ideas about how to use their expert panels.